Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Neoleukin Therapeutics In...

    NASDAQ: NLTX · Real-Time Price · USD
    3.49
    0.05 (1.45%)
    At close: Dec 18, 2023, 9:00 PM

    Neoleukin Therapeutics Statistics

    Share Statistics

    Neoleukin Therapeutics has 2.35M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 2.35M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 1,000

    FTD / Avg. Volume

    n/a
    		 18.12%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -2.01 and the forward PE ratio is null. Neoleukin Therapeutics's PEG ratio is 0.43.

    PE Ratio

    n/a
    		 -2.01

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 1.19

    P/FCF Ratio

    n/a
    		 -2.41

    PEG Ratio

    n/a
    		 0.43
    Financial Ratio History

    Enterprise Valuation

    Neoleukin Therapeutics has an Enterprise Value (EV) of 86.61M.

    EV / Sales

    n/a
    		 0

    EV / EBITDA

    n/a
    		 -1.53

    EV / EBIT

    n/a
    		 -1.9

    EV / FCF

    n/a
    		 -1.85

    Financial Position

    The company has a current ratio of 8.96, with a Debt / Equity ratio of 0.13.

    Current Ratio

    n/a
    		 8.96

    Quick Ratio

    n/a
    		 8.96

    Debt / Equity

    n/a
    		 0.13

    Debt / EBITDA

    n/a
    		 -0.21

    Debt / FCF

    n/a
    		 -0.26

    Interest Coverage

    n/a
    		 -37.36

    Financial Efficiency

    Return on Equity is -59.38% and Return on Invested Capital is -54.06%.

    Return on Equity

    n/a
    		 -59.38%

    Return on Assets

    n/a
    		 -48.31%

    Return on Invested Capital

    n/a
    		 -54.06%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-8,002,428.57

    Employee Count

    n/a
    		 7

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -1.54M

    Effective Tax Rate

    n/a
    		 2.68%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is 1.1, so Neoleukin Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.1

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 3.46

    200-Day Moving Average

    n/a
    		 3.73

    Relative Strength Index (RSI)

    n/a
    		 51.69

    Average Volume (20 Days)

    n/a
    		 5,520

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -59.1M

    Net Income

    n/a
    		 -56.02M

    EBITDA

    n/a
    		 -56.48M

    EBIT

    n/a
    		 -55.98M

    Earnings Per Share (EPS)

    n/a
    		 -1.01
    Full Income Statement

    Balance Sheet

    The company has 37.89M in cash and 12.07M in debt, giving a net cash position of 25.82M.

    Cash & Cash Equivalents

    n/a
    		 37.89M

    Total Debt

    n/a
    		 12.07M

    Net Cash

    n/a
    		 25.82M

    Retained Earnings

    n/a
    		 -451.06M

    Total Assets

    n/a
    		 89.59M

    Working Capital

    n/a
    		 74.68M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -45.61M and capital expenditures -1.11M, giving a free cash flow of -46.72M.

    Operating Cash Flow

    n/a
    		 -45.61M

    Capital Expenditures

    n/a
    		 -1.11M

    Free Cash Flow

    n/a
    		 -46.72M

    FCF Per Share

    n/a
    		 -4.23
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    NLTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -49.82%

    FCF Yield

    n/a
    		 -41.55%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for NLTX.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Dec 19, 2023. It was a backward split with a ratio of 1:4.

    Last Split Date

    n/a
    		 Dec 19, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:4

    Scores

    Altman Z-Score

    n/a
    		 -7.43

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist